Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:06 2024-04-30 am EDT			5-day change	1st Jan Change
3.225 ^GBX	-9.15%		-15.13%	-24.12%

Apr. 15	Fusion Antibodies inks commercial contract for OptiPhage library	AN
Apr. 15	Fusion Antibodies Secures Contract to Set Up OptiPhage Library	MT

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

February 01, 2024 at 07:02 am EST

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

The Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market said the receipt is regarding the company's financial year that ended at the end of March last year.

Chief Executive Officer Adrian Kinkaid said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."

Fusion Antibodies shares rose 9.5% to 5.20 pence each on Thursday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	HENNES & MAURITZ AB	176.8 SEK	-1.42%	-2.75%	26.42B
	FUSION ANTIBODIES PLC	3.225 GBX	-9.15%	-15.13%	4.25M

Latest news about Fusion Antibodies plc

Fusion Antibodies inks commercial contract for OptiPhage library	Apr. 15	AN
Fusion Antibodies Secures Contract to Set Up OptiPhage Library	Apr. 15	MT
Fusion Antibodies plc Enters into Commercial Contract to Develop a Bespoke OptiPhageTM Library	Apr. 15	CI
Sondrel wins USD23 million contract	Feb. 27	AN
Fusion Antibodies Lands Antibodies Contract with Diagnostics Company	Feb. 27	MT
Fusion Antibodies plc Receives First Purchase Order Under the Master Services Agreement	Feb. 27	CI
Fusion Antibodies raises GBP1.4 million via placing	Feb. 14	AN
Fusion Antibodies Raises GBP1 Million via Share Issue	Feb. 14	MT
Fusion Antibodies strikes follow-on research and development project	Feb. 06	AN
Fusion Antibodies Receives Follow-On Project from US Biotechnology Client	Feb. 06	MT
AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations	Feb. 06	AN
Fusion Antibodies plc Receives Follow-On Project Award and R&D Update	Feb. 06	CI
Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform	Feb. 01	AN
Fusion Antibodies Receives R&D Tax Credit from UK Government	Feb. 01	MT
FTSE 100 slips as miners hold down index	Dec. 04	AN
Fusion Antibodies shares fall with revenue despite "positive" outlook	Dec. 04	AN
AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations	Dec. 04	AN
Fusion Antibodies plc Reports Earnings Results for the Half Year Ended September 30, 2023	Dec. 04	CI
Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024	Dec. 04	CI
Fusion Antibodies Shares Rise on US Cancer Institute Collaboration	Nov. 28	DJ
Fusion Antibodies shares up on deal with US National Cancer Institute	Nov. 28	AN
AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow	Nov. 28	AN
Fusion Antibodies plc Announces That It Has Signed Collaboration Agreement with the National Cancer Institute for the Use of Optimal	Nov. 28	CI
FTSE 100 Ends Three-Day Falling Streak After Mixed Updates	Nov. 09	DJ
EARNINGS AND TRADING: Wincanton profit down; James Cropper ups payout	Nov. 09	AN

Chart Fusion Antibodies plc

Duration

Period

More charts

Company Profile

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FUSION ANTIBODIES PLC	-24.12%	4.25M
IQVIA HOLDINGS INC.	+0.43%	42.86B
MODERNA, INC.	+11.82%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.63%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.14%	18.63B
MEDPACE HOLDINGS, INC.	+27.65%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.78%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.28%	11.21B

Other Biotechnology & Medical Research

Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

Stocks mentioned in the article

Latest news about Fusion Antibodies plc

Chart Fusion Antibodies plc

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research